Skin And Soft Tissue Infections - Pipeline Review, H2 2017

Global Markets Direct’s, ‘Skin And Soft Tissue Infections - Pipeline Review, H2 2017’, provides an overview of the Skin And Soft Tissue Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Skin And Soft Tissue Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Skin And Soft Tissue Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections

The report reviews pipeline therapeutics for Skin And Soft Tissue Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Skin And Soft Tissue Infections therapeutics and enlists all their major and minor projects

The report assesses Skin And Soft Tissue Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Skin And Soft Tissue Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Atox Bio Ltd

CorMedix Inc

Takeda Pharmaceutical Company Ltd

Valevia UK Ltd

Wockhardt Ltd

Atox Bio Ltd

CorMedix Inc

Takeda Pharmaceutical Company Ltd

Valevia UK Ltd

Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Skin And Soft Tissue Infections - Overview

Skin And Soft Tissue ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Skin And Soft Tissue Infections - Overview

Skin And Soft Tissue Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Skin And Soft Tissue Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development

Atox Bio Ltd

CorMedix Inc

Takeda Pharmaceutical Company Ltd

Valevia UK Ltd

Wockhardt Ltd

Skin And Soft Tissue Infections - Drug Profiles

ADEP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alalevonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceftaroline fosamil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRMD-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7072 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Skin and Soft Tissue Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Skin And Soft Tissue Infections - Dormant Projects

Skin And Soft Tissue Infections - Product Development Milestones

Featured News & Press Releases

May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections

Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority

Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections

Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial

Sep 10, 2012: Atox Bio’s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections

Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Skin And Soft Tissue Infections, H2 2017

Number of Products under Development by Companies, H2 2017 ...

List of Tables

Number of Products under Development for Skin And Soft Tissue Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Skin And Soft Tissue Infections - Pipeline by Atox Bio Ltd, H2 2017

Skin And Soft Tissue Infections - Pipeline by CorMedix Inc, H2 2017

Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Skin And Soft Tissue Infections - Pipeline by Valevia UK Ltd, H2 2017

Skin And Soft Tissue Infections - Pipeline by Wockhardt Ltd, H2 2017

Skin And Soft Tissue Infections - Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Skin And Soft Tissue Infections, H2 2017

Number of Products under Development by Companies, H2 2017 ...

List of Figures

Number of Products under Development for Skin And Soft Tissue Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports